about
Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma.Monoclonal antibodies: the new magic bullets for allergy: IUPHAR Review 17.New fronts emerge in the influenza cytokine storm.Update on reslizumab for eosinophilic asthma.Human Bronchial Epithelial Cell-Derived Factors from Severe Asthmatic Subjects Stimulate Eosinophil Differentiation.Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.Mepolizumab in the treatment of severe eosinophilic asthma.Role of Eosinophil Granulocytes in Allergic Airway Inflammation Endotypes.Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations.Inflammatory biomarkers for asthma endotyping and consequent personalized therapy.Analysis of changes in expression of IL-4/IL-13/STAT6 pathway and correlation with the selected clinical parameters in patients with atopic asthma.Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma.Asthma Endotypes and an Overview of Targeted Therapy for Asthma.Interleukin-5 Mediates Parasite-Induced Protection against Experimental Autoimmune Encephalomyelitis: Association with Induction of Antigen-Specific CD4+CD25+ T Regulatory Cells.The Protective Effects of Astaxanthin on the OVA-Induced Asthma Mice Model.New approaches for identifying and testing potential new anti-asthma agents.Anti-IgE and Biologic Approaches for the Treatment of Asthma.Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.Activation of group 2 innate lymphoid cells exacerbates and confers corticosteroid resistance to mouse nasal type 2 inflammation.
P2860
Q33581536-34BBB5BF-045F-4B3F-A2DF-60ABF35AADB5Q36599623-3BC0536D-C0A5-41F3-8BCC-256AC1B48643Q38400762-CC70B799-267B-4122-A227-F0A3320AE300Q38587334-EF283015-4F46-4D57-924B-76C99E9A39DDQ38602337-1E62E33F-FEB3-4B9B-9494-5977EA53857EQ38661881-ADE0F43B-8B43-436E-BB7E-0F710EA7BC3FQ38664948-46C904B4-51F8-4CA3-BA29-7F5E0B9757F5Q38831891-33F7703F-742A-476D-BDF1-88F015CE9146Q39189229-DECF3694-A016-4185-9E39-8CADF5C62A03Q39202765-BE1820FE-5B19-4226-9988-DF285A581782Q40092918-EC476BE8-99C7-4FC5-A1F6-5969BBABB171Q41605623-A34A1301-18AC-4D74-A795-59A6FDAAE4F9Q42146218-01AA4038-4198-4D63-8D87-48603EE5C517Q47160078-0BF04DA9-EA7C-4176-8059-78B9A8AEF162Q47704366-843BCDBB-812B-4366-9D0E-DA66FB631875Q47873103-08EC6BA0-BE2C-415A-B9B2-D7D7483CB728Q50120034-CB80ACBE-7840-4CF4-AB09-202BDF65CC79Q51563764-D81F62EB-9354-4C30-9AE2-A22753F16B19Q53738990-79EB4BA0-9E93-4612-AB1B-F899B57C741C
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականին հրատարակուած գիտական յօդուած
@hyw
2014 թվականին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Anti-IL5 therapy for asthma and beyond
@ast
Anti-IL5 therapy for asthma and beyond
@en
Anti-IL5 therapy for asthma and beyond
@nl
type
label
Anti-IL5 therapy for asthma and beyond
@ast
Anti-IL5 therapy for asthma and beyond
@en
Anti-IL5 therapy for asthma and beyond
@nl
prefLabel
Anti-IL5 therapy for asthma and beyond
@ast
Anti-IL5 therapy for asthma and beyond
@en
Anti-IL5 therapy for asthma and beyond
@nl
P2860
P356
P1476
Anti-IL5 therapy for asthma and beyond
@en
P2093
Parameswaran Nair
Roma Sehmi
P2860
P2888
P356
10.1186/1939-4551-7-32
P407
P577
2014-01-01T00:00:00Z
P5875
P6179
1009192250